Regulatory News Service
27 Feb, 2008 Latest Developments
13 Feb, 2008 Holding(s) in Company
05 Feb, 2008 Holding(s) in Company
11 Jan, 2008 Holding(s) in Company
19 Dec, 2007 Holding(s) in Company
29 Nov, 2007 Interim Results
28 Sep, 2007 Total Voting Rights
25 Sep, 2007 Holding(s) in Company
18 Sep, 2007 Additional Listing
06 Sep, 2007 Holding(s) in Company
05 Sep, 2007 Director/PDMR Shareholding04 Sep, 2007 Directorate Change
31 Aug, 2007 Total Voting Rights
16 Aug, 2007 Aim Rule 26 Information
06 Aug, 2007 Additional Listing
01 Aug, 2007 Director/PDMR Shareholding
01 Aug, 2007 Total Voting Rights
30 Jul, 2007 Joint Venture
30 Jul, 2007 AGM Statement
20 Jun, 2007 Annual Report and Accounts
08 Jun, 2007 Additional Listing
04 Jun, 2007 New Global Contract
18 Apr, 2007 Trading Statement
30 Mar, 2007 Total Voting Rights
22 Mar, 2007 Holding(s)in Company
19 Mar, 2007 Holding(s)in Company
19 Mar, 2007 Holding(s)in Company
19 Mar, 2007 Holding(s)in Company
19 Mar, 2007 Holding(s)in Company
13 Mar, 2007 Additional Listing
28 Feb, 2007 Total Voting Rights
23 Feb, 2007 Additional Listing
21 Feb, 2007 Director/PDMR Shareholding
08 Feb, 2007 Additional Listing
05 Feb, 2007 Holding(s)in Company
19 Jan, 2007 Total Voting Rights
12 Jan, 2007 Issue of Equity
14 Dec, 2006 Total Voting Rights
11 Dec, 2006 Interim Results
27 Nov, 2006 Board Appointment
14 Nov, 2006 Synergy Healthcare Agreement
01 Nov, 2006 Issue of Equity
26 Oct, 2006 Distribution Agreements
11 Sep, 2006 Change of Adviser
LATEST DEVELOPMENTS
Byotrol plc ("Byotrol" or the "Company"), the leading anti-microbial technology
company is pleased to be able to provide an update on recent developments across
the business.
Agricultural Sector - Contract
The Company has secured a contract to supply The Active Group, a UK based
producer and distributor of agricultural products, with a range of hoof and teat
care products containing Byotrol technology in both concentrate and pre-mix form
for use by livestock farmers. Products to the value of £250,000 are to be
delivered in March 2008 and the annual call off is expected to be around £1
million in the first year.
The Directors of Byotrol believe the dairy cattle sector will be an important
market for the Company and expenditure on sanitising products is estimated to be
worth in excess of £35 million per annum in the UK, with equally significant
opportunities in Western Europe and North America.
The Company's teat and hoof care products were launched at one of the UK's
leading agricultural events, the Royal Bath and West of England Dairy Show, in
January this year.
Food Sector - Marks and Spencer ("M&S") Accreditation and Heinz Order
The Company is very pleased to report that M&S has approved Byosan as an
Approved Terminal Disinfectant for use within M&S's Food Manufacturing Supply
Chain. Accordingly, Byotrol is now approved to supply organisations that process
and manufacture food products on behalf of M&S.
Approval was granted following an eight month, three stage project involving
initial laboratory verification of the technology by the Campden and Chorleywood
Food Research Association followed by a period of commercial validation
conducted by Pennine Foods (part of Northern Foods). Hygiene, technical and
final commercial validation was conducted in conjunction with Pennine Foods.
In the Director's opinion the approval with M&S opens up potentially significant
sales opportunities following the approval with one of the UK's most reputable
food retailers. It also opens up sales opportunities within Northern Foods, as a
result of the work conducted with Pennine Foods.
The Company has also secured its first order to supply food manufacturer H J
Heinz with Byotrol technology in one of its facilities in Cumbria. The initial
order follows extensive evaluation conducted by H J Heinz to establish the
efficacy of the Byotrol technology. Studies of Byotrol products are being
conducted at other Heinz sites.
Healthcare Sector - Care UK Deployment Complete and Pre-School Care Order
The Company's health distribution partner, Synergy Healthcare, has completed the
installation of more than 4,000 hand dispensers that use hand hygiene products
containing Byotrol technology into Care UK, a leading independent provider of
health and social care service solutions. The completion of this installation
will lead to an annual ongoing provision of product to Care UK.
The Company has also secured an initial order for £30,000 of product to be
supplied for use in the pre-school and playgroup sectors where Byotrol
technology is being used under the Toyguard brand to enable playgroup operators
to clean equipment and toys used in the pre-school setting.
Consumer Products
Byotrol's joint venture, Byotrol Consumer Products limited, set up with leading
innovation company What If, continues to make strong progress with a number of
leading companies in the target consumer goods sectors and the business plan for
this joint venture is in line with the original timescales set out at the time
of launch.
Commenting on these developments Stephen Falder, Deputy Chairman of Byotrol plc
said:- "In the food sector we have set out to secure accreditation and orders at
the very highest level with three of the UK's leading food manufacturers. These
pave the way for sales right across the food industry supply chain.
"We are now starting to demonstrate commercial returns across a number of
sectors and are looking to build on these successes in the months ahead."
TOTAL VOTING RIGHTS
In accordance with the Financial Services Authority's Disclosure and
Transparency Rules, the total number of ordinary shares of 0.25p of Byotrol in
issue as at the date of this notice is 44,662,335 with each share carrying the
right to one vote.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in Byotrol, under the Disclosure and
Transparency Rules.
28 September 2007
Contact:
Charles Stanley Securities
(Nominated Adviser and Broker)
Adam Sumner Tel 020 7149 6000
ADDITIONAL LISTING
The Board announces that, following the exercise of warrants, 192,458 ordinary
shares in the Company have been issued.
Accordingly, application has been made for 192,458 new ordinary shares to be
admitted to trading on AIM and it is expected that admission will take place on
24 September 2007.
The new ordinary shares will rank pari passu with the existing shares of the
Company. Following this allotment, the total issued share capital of the Company
will increase to 44,662,335 ordinary shares.
HOLDING(S) IN COMPANY
Byotrol PLC
06 September 2007
TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to
which voting rights are attached (ii):
Byotrol Plc
2. Reason for the notification (please state Yes/No): ( )
An acquisition or disposal of voting rights: ( X )
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached: ( )
An event changing the breakdown of voting rights: ( )
Other (please specify): ( )
3. Full name of person(s) subject to the notification obligation (iii):
Aberdeen Asset Management
PLC's Fund Management
Operating Subsidiaries
4. Full name of shareholder(s) (if different from 3.) (iv): N/A
5. Date of the transaction (and date on which the threshold is crossed or
reached if different) (v): 24/08/2007
6. Date on which issuer notified: 05/09/2007
7. Threshold(s) that is/are crossed or reached: 5%
8. Notified details:
Aberdeen's holding has increased due to the acquisition of Glasgow Investment Managers Limited.
A: Voting rights attached to shares
Class/type of shares if possible Situation previous to the Triggering transaction (vi)
using the ISIN CODE
Number of shares Number of voting Rights (viii)
GB00B0999995 0 0
Resulting situation after the triggering transaction (vii)
Class/type of shares if Number of shares Number of voting rights (ix) % of voting rights
possible using the ISIN CODE
Direct Direct (x) Indirect (xi) Direct Indirect
GB00B0999995 2,325,535 2,325,535 5.23
B: Financial Instruments
Resulting situation after the triggering transaction (xii)
Type of Expiration Date Exercise/Conversion Number of voting rights % of voting rights
financial (xiii) Period/ Date (xiv) that may be acquired if the
instrument instrument is exercised/
converted.
Total (A+B)
Number of voting rights % of voting rights
2,325,535 5.23
9. Chain of controlled undertakings through which the voting rights and/or
the financial instruments are effectively held, if applicable (xv): N/A
Proxy Voting:
10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will cease to hold: N/A
12. Date on which proxy holder will cease to hold voting rights: N/A
13. Additional information:N/A
14. Contact name: Michael Tay
15. Contact telephone number: 01224 425 103
DIRECTOR'S SHAREHOLDING
The Board of Byotrol announces that it has today granted 50,000 options exercisable at 41p per share pursuant to the Byotrol Unapproved Share Option Scheme, to a Non-Executive Director, Adrian J.R. Smith.
These options are exercisable at any time between 5 September 2009 and 4 September 2017 subject to the closing mid-market share price of Byotrol being not less than 180p each business day for a consecutive period of three months. These options represent Mr Smith's only interests in the share capital of the Company.
5 Sep 2007
DIRECTORATE CHANGE
The Board of Byotrol is pleased to announce the appointment of Mr. Adrian J.R. Smith as Non-Executive Director of the Company with immediate effect.
Adrian Smith started his business career at Procter & Gamble Ltd in 1966 and served 13 years in both sales and brand management positions. He also spent 11 years at Ecolab Inc. in Europe and the United States as a senior international executive. He is currently the Chief Executive of The Woolton Group LLC, and is the non-executive chairman of Gaming VC S.A. He is also a non-executive director at Tutogen Inc. in Alachua, Florida. Before retiring from Deloitte Touche Tohmatsu in 2004, Adrian served as the CEO of Grant Thornton LLP and as a worldwide managing partner for marketing at Arthur Andersen from 1992 until 1997.
David McRobbie, Chief Executive Officer, commented 'I am delighted to welcome Adrian Smith to our board. His experience in certain of our target markets and his varied business strengths will add to the quality of our Board'
Adrian John Russell Smith, aged 62, holds or has held the following directorships:
Current Directorships & Partnerships
Invensco LLP
Woolton Group LLC
Tutogen Inc.
Gaming VC S.A.
The Education Foundation of Indian River County
Past Directorships & Partnerships
Carter & Carter Group plc
Harbor Branch Oceanographic Institute
Grant Thornton LLP
Deloitte & Touche LLP
Arthur Andersen LLP
There are no other details required to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.
4 Sept 2007
TOTAL VOTING RIGHTS
In accordance with the Financial Services Authority's Disclosure and Transparency Rules, the total number of ordinary shares of 0.25p of Byotrol in issue as at the date of this notice is 44,469,877 with each share carrying the right to one vote.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in Byotrol, under the Disclosure and Transparency Rules.
31 August 2007
AIM 26 RULE INFORMATION
The Company announces that information required by AIM Rule 26 (company information disclosure) is available on the Company's website: www.byotrol.com.
16 August 2007
ADDITIONAL LISTING
The Board announces that following the exercise of warrants 275,000 ordinary shares in the Company have been issued.
Accordingly, application has been made for 275,000 new ordinary shares to be admitted to trading on AIM and it is expected that admission will take place on 10 August 2007.
The new ordinary shares will rank pari passu with the existing shares of the Company. Following this allotment, the total issued share capital of the Company will increase to 44,469,877 ordinary shares.
6 August 2007
TOTAL VOTING RIGHTS
In accordance with the Financial Services Authority's Disclosure and Transparency Rules, the total number of ordinary shares of 0.25p of Byotrol in issue as at the date of this notice is 44,194,877 with each share carrying the right to one vote.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in Byotrol, under the Disclosure and
Transparency Rules.
1 August 2007
BYOTROL plc SIGNS JOINT VENTURE WITH CONSUMER INNOVATION EXPERTS
The Directors of Byotrol plc ('Byotrol' or the 'Company') are pleased to
announce the signing of a joint venture with What If Ventures, the investment
arm of What If Holdings Ltd, the holding company of the world's largest
independent consumer innovation company.
The joint venture will be called Byotrol Consumer Products Limited ('BCP') and
will provide the vehicle through which the Company will pursue opportunities for
its anti-microbial technology in global consumer markets. BCP will pursue a
similar strategy to Byotrol, seeking to exploit its technology by entering
licence agreements with leading Fast Moving Consumer Goods companies ('FMCG').
The Board recognises that the skills, expense and timeframes required in
launching new consumer products require a partner with a proven track record in
the FMCG sector. What If Ventures and its group have that track record, as well
as leading-edge global consumer insight skills, new product development
expertise and access to the world's major consumer product businesses.
In the opinion of the Directors, BCP represents the most appropriate structure
to maximise the significant opportunity presented by the consumer marketplace.
The Board expects the combination of Byotrol and What If Ventures to short cut
the often lengthy and expensive new product development process within FMCG
businesses and bring the Byotrol anti-microbial technology to the largest
possible audience at the fastest possible pace.
Byotrol Consumer Products Limited
Background
Having identified What If Ventures as the most appropriate partner, the Board
has worked closely with the What If Ventures team since the beginning of 2007.
Considerable work has been undertaken ahead of the formation of the joint
venture in order to maximise the opportunities available to it from today
onwards.
During 2007, the joint venture partners have invested considerable time, money
and resource in planning BCP, including strengthening the patent framework,
developing and testing products, developing consumer insights and consumer
propositions, market scoping and target licensee development.
More specifically, focus groups were conducted in the United Kingdom, United
States, Europe, China and India. Within these groups the response to the
Byotrol anti-microbial technology was encouraging.
The market opportunity
Based on initial research carried out by BCP, the Byotrol anti-microbial
technology is relevant to several multi-billion dollar global consumer markets.
There are a number of specific applications within the consumer marketplace that
BCP has identified, where there is the potential to add value to products
through the addition of Byotrol's technology.
Strategy
The strategy pursued by BCP will be similar to that already in place within
Byotrol, in that licensees will be sought from amongst the leading global FMCG
companies. It is expected that BCP will receive principally a mixture of
initial fees and on-going royalties where the Byotrol technology is used.
In the next two years, BCP will focus on concluding two major types of licensee
opportunities. In particular, BCP will seek to partner with a global FMCG
business and will also examine opportunities with companies which have specific
niche opportunities whether on a regional or global basis.
Inevitably, each potential licensee will require time to assess the opportunity
whilst BCP will aim to ensure the optimum combination of licensees. In FMCG
businesses, new product launches can typically take many years from inception to
profitability. The Directors believe however that the addition of What If
Ventures' consumer insight, innovation expertise and high level corporate access
will have a significant impact on the time taken to introduce product to the
market.
The board of BCP currently expects that the company will break even within
approximately two years. However it is not anticipated that the company's start
up costs will be significant ahead of that time.
The joint venture
An agreement has today been signed that establishes Byotrol Consumer Products
Limited as a 50:50 joint venture between Byotrol and What If Ventures'
investment vehicle, What If Innovation Capital Nominees Ltd ('WIICN'). Both
companies have committed to invest £250,000 during the first year of operation.
Initially, BCP will draw directly upon resources and expertise within Byotrol
and What If Ventures before recruiting the appropriate longer term management
team in due course.
The board of Byotrol Consumer Products will comprise David McRobbie (Chief
Executive, Byotrol), Stephen Falder (Deputy Chairman, Byotrol), Richard Bell
(Finance Director, Byotrol), David Traynor (Director, WIICN), David Allan
(Director, WIICN) and Julia Hoare (Director and Company Secretary, WIICN). In
addition, BCP will be able top draw upon the knowledge and expertise of senior
advisers with backgrounds in FMCG operations.
Byotrol plc Chief Executive David McRobbie said: 'This joint venture will allow
us to fast track our technology to the consumer market place. What If Ventures
and its group's proven track record working with FMCG companies, its network of
contacts, its consumer knowledge and its insight and marketing expertise are a
perfect fit with our scientific and technical innovation skills.
'For Byotrol alone, launching a consumer brand from scratch would be a massive
financial undertaking with significant risk attached. By partnering with What If
Ventures, we are aiming to capture a substantial amount of market share without
the risk or cost associated with a conventional entry into the consumer market
place.
Importantly, the establishment of this joint venture also allows us to maintain
a strong focus on our core business in the healthcare, food, agriculture and
industry sectors.'
David Allan of What If Ventures added: 'We believe Byotrol is a very significant
technology which will deliver real innovation and significant benefits to
consumers. Our initial research show the technology has the potential to cross a
number of hygiene markets in home and personal care from anti bacterial
protection of the kitchen and bathroom to skin care and pet care. What If
Ventures is ideally positioned to help develop the consumer business and help
introduce Byotrol to some of the world's leading FMCG businesses.'
More information on What If Ventures can be found at: http://www.whatifinnovation.com/Ventures
30 July 2007
AGM STATEMENT
The Board of Byotrol Plc announces that all of the resolutions considered at the
Annual General Meeting held today were approved by shareholders.
30 July 2007
ADDITIONAL LISTING
The Board announces that following the exercise of warrants 565,600 ordinary shares in the Company have been issued.
Accordingly, application has been made for 565,600 new ordinary shares to be admitted to trading on AIM and it is expected that admission will take place on 15 June 2007.
The new ordinary shares will rank pari passu with the existing shares of the
Company. Following this allotment, the total issued share capital of the Company
will increase to 44,194,877 ordinary shares.
8 June 2007
BYOTROL NEW GLOBAL CONTRACT ANNOUNCEMENT
The Directors of Byotrol plc (the 'Company') are pleased to be able to report a
new global contract that has been secured by the Company.
The Company has worked in partnership to develop a range of products
incorporating Byotrol(R) technology for Fellowes Inc, a leading global provider
of office accessories and business machines.
As a global provider, Fellowes has access to a wide range of disinfectant
technologies and chose Byotrol for its residual efficacy, ultra low toxicity
profile and broadband action against a wide range of micro-organisms.
Fellowes is launching the Virashield(TM) range of products containing Byotrol
across Europe with a global launch planned in the near future. The range, which
includes wipes and hand protection foam, is designed to help combat the spread
of infections in the workplace.
Virashield(TM) offers both residual efficacy of
up to seven days coupled with broad spectrum capability against a wide range of
organisms including viruses such as influenza and avian flu and bacteria
including E.coli. Research has shown that a typical office desk harbours up to
400 times more bacteria than a typical toilet seat and the residual efficacy
offered by the Virashield range containing Byotrol will help office workers
combat this real and growing risk of infection.
The Virashield(TM) range has been extensively tested by both Byotrol and
Fellowes and the tests have proven the product's efficacy for up to seven days
following application. The range can both remove microbes from surfaces in an
office environment and keep the surface microbially clean for this period of
time.
Byotrol plc Chief Executive David McRobbie said, 'We are delighted to have
secured our first contract that will make Byotrol available on a global basis
and that a company the size of Fellowes chose Byotrol as its worldwide strategic
partner for this key product launch. There is growing awareness that
micro-organisms are not just an issue in hospitals and specialist environments
and that effective cleaning regimes have a role in a wider range of settings.'
Headquartered in Illinois, USA with subsidiaries in Canada, Benelux, France,
Germany, Italy, Poland, Spain, UK, China, Singapore, Japan, Korea and Australia,
they have an extensive distribution & export network reaching over 100
countries. Fellowes employs more than 2,700 people throughout the world and
expects global sales in excess of $700 million this year.
4 Jun 2007
UPDATE ON TRADING AND RESULTS OF INDEPENDENT TRIAL
The Directors of Byotrol plc (the 'Company') are pleased to be able to provide
an update on the recent strong progress made across the group following the end
of its financial year to 31 March 2007 and to report that direct product sales
revenues will be in line with the Directors' expectations and in the last
quarter of the financial year £240,000 of sales orders were delivered.
The Company has made significant progress across all of its target markets in the year to 31 March 2007 and has been successful in attracting a number of new clients with global scale which the Directors believe will generate significant new sales revenue to the Company.
Within the UK industrial medical sector Byotrol is pleased to be able to announce it has recently shipped an order for more than 20,000 litres of Byotrol concentrates which will be used in a speciality medical application.
The Company is also working on a number of new applications for Byotrol where the Directors see significant opportunities for sale of Byotrol. By way of example, a number of leading UK agricultural distributors have recently placed orders with the Company for disinfectant and wipe products containing Byotrol's technology. Similarly in the pet care niche, sales of a range of grooming products containing Byotrol in leading retailer Pets at Home have significantly exceeded projections and the product range was recently recognised as new product of the year by Pets At Home
The Company's ongoing testing and validation programme has also made strong progress and the Directors are pleased to be able to announce the publication of a North American study detailing the positive effects of the Company's Polysphere(R) product in battling multidrug-resistant organisms ('MDROs'). This study has resulted in the participating hospital incorporating Byotrol products into its cleaning regime and this represents a very encouraging step in penetrating the US healthcare market.
The study, carried out by hospital based researchers at Monroe Hospital,
Bloomington, Indiana found that Polysphere(R) provided 'residual disinfecting
properties to surfaces that may become contaminated by MDROs' and that in
particular it was 'effective for up to three (consecutive) days post treatment'.
All surfaces were inoculated using Vancomycin Resistant Enterococcus faecalis ('
VRE') and Methicillin Resistant Staphylococcus Aureus ('MRSA'). The study found
that for three consecutive days no growth of VRE occurred and that growth of
MRSA was so sparse that it 'could be considered no growth'.
The full text of the paper can be found by following this link: here
Commenting on the recent successes Byotrol plc Chief Executive David McRobbie said:'These recent successes demonstrate our ability to commercialise an innovative technology and generate future revenue streams across our target markets. Equally pleasing is the successful study within North America because this validates our technology in another marketplace. Importantly the work at Monroe Hospital demonstrates our ability to establish a trial that proves the efficacy of our technology and to convert that into product sales in the highly demanding US healthcare market.'
The preliminary results for the year ended 31 March 2007 are expected to be
announced in June 2007.
18 April 2007
TOTAL VOTING RIGHTS
In accordance with the Financial Services Authority's Disclosure and Transparency Rules, the total number of ordinary shares of 0.25p of Byotrol in issue as at the date of this notice is 43,629,277 with each share carrying the right to one vote.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in Byotrol, under the Disclosure and Transparency Rules.
30 March 2007
ADDITIONAL LISTING
13 Mar 2007 TOTAL VOTING RIGHTS 28 Feb 2007 ADDITIONAL LISTING
DIRECTOR/PDMR SHAREHOLDING
1. 225,000 options exercisable at 78.5p per share pursuant to the Byotrol
Unapproved Share Option Scheme, to the Chief Executive, David McRobbie. 2. 100,000 options exercisable at 78.5p per share pursuant to the Byotrol
Unapproved Share Option Scheme and 125,000 options exercisable at 78.5p per
share pursuant to the Byotrol EMI Share Option Scheme, to the Deputy Chairman,Stephen Falder. 3. 50,000 options exercisable at 78.5p per share pursuant to the Byotrol
Unapproved Share Option Scheme, to the Finance Director, Richard Bell. All options were granted by the remuneration committee on 20 February 2007. Following the grant of these options, the directors have the following
interests: D. McRobbie S. Falder R. Bell
No.of options granted 225,00 225,00 50,00 Total No of shares under option 225,00 225,00 50,00 21 Feb 2007 ADDITIONAL LISTING
In addition, the Board announces that 14,000 new ordinary shares in the Company
have been issued to a new employee of the Company and 1,500 new ordinary shares
each have been issued to Professor Curtis Gemmell and Dr Ralph Portier, both of
whom are advisers to the Company. Accordingly, application has been made for 112,200 new ordinary shares to be
admitted to trading on AIM and it is expected that admission will take place on
14 February 2007. The new ordinary shares will rank pari passu with the existing shares of the
Company. Following this allotment, the total issued share capital of the Company
will increase to 43,400,049 ordinary shares. HOLDING(S) IN COMPANY
TOTAL VOTING RIGHTS
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in Byotrol, under the Disclosure and
Transparency Rules. ISSUE OF EQUITY
Accordingly, application has been made for the 75,000 new ordinary shares to be
admitted to trading on AIM and it is expected that admission will take place on
15 January 2007. The new ordinary shares will rank pari passu with the existing shares of the
Company. Following this allotment, the total issued share capital of the Company
will increase to 43,287,849 ordinary shares. TOTAL VOTING RIGHTS
14 December 2006 BOARD APPOINTMENT
Mr Bell is 55 years old. He qualified as a Chartered Accountant in 1975 and was
registered as an FCA in 1982. He left the profession in 1979 and joined Fisons
Plc, where he held several roles in both group head office and the horticulture
division. Mr Bell worked at Barr & Wallace Arnold Trust plc from 1986 to 1998
and was Group Financial Director from 1995. He was Chief Operating Officer of
Sandicliffe Motor Group Limited from 1998 to 2000. From 2000 until the present
he has been a Director of Bedingham Bell Limited, a consultancy providing
financial and general management services. Other than the above, Mr Bell is also currently a director of Bradford Teaching
Hospitals NHS Foundation Trust and Red Labell Limited. Within the last five years, Mr Bell has also been a Director of Smart Approach
Group plc and Smart Approach Limited from 2005 to 2006. Both companies entered
administration on 2 February 2006 with liabilities owing to creditors of£527,000 of which £247,000 was due to directors. The Company confirms that no other details are required to be disclosed under
paragraph (g) of Schedule 2 of the AIM Rules. The Company also announces that it expects to release its interim results on
11 December 2006. 27 November 2006 AGREEMENT WITH SYNERGY HEALTHCARE PLC The Directors of Byotrol plc (the 'Company') are pleased to announce that the
Company has entered into an agreement with Synergy Healthcare plc ('Synergy')
which will see Byotrol's anti-microbial technology deployed into the NHS and
independent healthcare sector in the UK and the rest of the world. Synergy Healthcare plc is a leading provider of outsourced medical services to
the UK and the Netherlands, with an annualised turnover of over £130million and
has over 2500 employees. Synergy has been providing sterile services in the UK
since 1996 and is the UK's largest provider of decontamination and sterile
services for surgical instruments. The Company operates fifteen facilities and
processing approximately 40 million instruments per annum. The agreement will give Synergy the use of Byotrol technology in significant
healthcare markets for licences, fees and options totalling £2.3 million
together with an advance royalty payment of £400,000. In addition to fees and royalties, Synergy will be purchasing Byotrol
concentrates for use in manufacture of anti-microbial products. 'This agreement will see the rapid commercialisation of Byotrol technology in
the healthcare market and demonstrates our ability to licence the Company's
technology to a major organisation allowing us to gain a significant and rapid
penetration into one of our chosen key markets. We continue to progress discussions with several major multinationals regarding
an increasing number of opportunities that have been recently identified in the
Company's other target markets of Food Processing and Industrial & Technical.' 14 November 2006
PLACING TO RAISE £5 MILLION TO ACCELERATE GROWTH
DISTRIBUTION AGREEMENTS
CHANGE OF ADVISER
11 Sep 2006
The Board announces that following the exercise of warrants 50,500 ordinary
shares in the Company have been issued.
Accordingly, application has been made for 50,500 new ordinary shares to be
admitted to trading on AIM and it is expected that admission will take place on
19 March 2007.
The new ordinary shares will rank pari passu with the existing shares of the
Company. Following this allotment, the total issued share capital of the Company
will increase to 43,629,277 ordinary shares.
In accordance with the Financial Services Authority's Disclosure and
Transparency Rules, the total number of ordinary shares of 0.25p of Byotrol in
issue as at the date of this notice is 43,578,777 with each share carrying the
right to one vote.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in Byotrol, under the Disclosure and
Transparency Rules.
The Board announces that following the exercise of warrants 178,728 ordinary
shares in the Company have been issued. Accordingly, application has been made for 178,728 new ordinary shares to be
admitted to trading on AIM and it is expected that admission will take place on
27 February 2007.
The new ordinary shares will rank pari passu with the existing shares of the
Company. Following this allotment, the total issued share capital of the Company
will increase to 43,578,777 ordinary shares.
23 February 2007
The Board of Byotrol announces that it has granted the following options to
Directors of the Company:
All
options are exercisable at any time between 21 February 2009 and 20 February
2017 subject to the closing mid-market share price of Byotrol being not less
than £1.80 each business day for a consecutive period of three months.
% of issued capital 0.25% 0.25% 0.25%
Existing shareholding 3,647,617 4,787,757 10,000
% of issued capital issued 8.40% 11.03% 0.02%
The Board announces that following the exercise of warrants 95,200 ordinary
shares in the Company have been issued.
8 February 2007
The Company has received notification that as at 19 January 2007 AXA S.A. and
its Group Companies had a beneficial interest in 1,350,000 ordinary shares in
Byotrol, representing 3.12 per cent. of the total voting rights in the Company's
ordinary share capital.
5 February 2007
For the purposes of the transitional provisions of the Financial Services
Authority's Disclosure and Transparency Rules, the total number of ordinary
shares of 0.25p of Byotrol in issue as at the date of this notice is 43,287,849
with each share carrying the right to one vote.
19 January 2007
The Board announces that following the exercise of warrants 75,000 ordinary
shares have been issued.
12 January 2007
For the purposes of the transitional provision of the Financial Services
Authority's Disclosure and Transparency Rules, the total number of ordinary
shares of 0.25p of Byotrol in issue as at the date of this notice is 43,212,849
with each share carrying the right to one vote.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in Byotrol, under the Disclosure and
Transparency Rules.
The Board of Byotrol announces today the appointment of Richard William Bell as
part-time Finance Director, with effect from 1 December 2006.
The contract gives Synergy exclusive sales and distribution rights to Byotrol's
technology in the healthcare market. In addition Synergy will market, sell and
distribute Byotrol's Assure product range to the NHS and Byotrol's existing
healthcare customers. In the UK, Synergy will assume responsibility for
supplying products containing Byotrol to Byotrol's existing healthcare users,
Sun Choice Europe Limited and DBM Holdings Ltd.
The agreement commences immediately with the UK market and incorporates options
that will grant similar rights to Synergy for both USA, Europe and the rest of
the world and these are exercisable between February 2007 and February 2008.
The agreement with Synergy demonstrates Byotrol's strategy to deploy its
technology in partnership with leading businesses in its chosen markets.
According to Stephen Falder, Deputy Chairman of Byotrol plc:
Dr Richard Steeves, Chief Executive of Synergy Healthcare, commented:
'The acquisition of the worldwide rights for Byotrol is a major strategic step forward for Synergy. Byotrol is an ideal fit for Synergy and, coupled with AirCleanse will greatly enhance our product offering in the atmospheric decontamination market. This is an area of critical concern to the healthcare market worldwide in order to counteract the ever-increasing threat of hospital
acquired infections.'
The Board of Byotrol plc (the 'Company') is pleased to announce that Charles
Stanley Securities has, on behalf of the Company, completed a placing (the
'Placing') of 8.34 million new Ordinary Shares of 0.25p each (the 'Placing
Shares') at 60 pence per share to raise approximately £4.6 million, net of
expenses.
The funds will be used by the Directors to address an increasing number of
opportunities that have been recently identified in the Company's target markets
of Healthcare, Food Processing and Industrial & Technical.
The Company recently obtained CE Marking status approving Byotrol for sale in
medical and disinfectant products in Europe and approval from the US Environment
Protection Agency for Byotrol to be used as a disinfectant, sanitiser and anti-
microbial product in a broad number of market sectors. As a result the Company
has been approached by several major multinationals interested in gaining access
to the Company's technology and the Company is currently engaged in discussions
with a number of these companies regarding the sale and/or licensing of Byotrol.
It is expected that the placing proceeds will assist the progress of such
discussions.
The Placing Shares will, when issued and fully paid, rank pari passu in all
respects with the existing issued ordinary shares of the Company.
The Placing is not a rights issue or open offer and the Placing Shares will not
be offered generally to Shareholders, whether on a pre-emptive basis or
otherwise. The Directors believe that the considerable extra cost and delay
involved in a rights issue or open offer would not be in the best interests of
the Company in the circumstances.
Richard Bell, a consultant to the Company, has acquired 10,000 Placing Shares,
pursuant to the Placing, and accordingly now owns 10,000 Ordinary Shares in the
Company.
Application has been made for the Placing Shares to be admitted to trading on
AIM and trading in the Placing Shares is expected to commence on Tuesday 7
November 2006. Following the admission of the Placing Shares to trading on AIM,
the Company will have 43,212,849 Ordinary Shares in issue.
Charles Stanley Securities has also placed a further 1,500,000 ordinary shares
on behalf of Mr Ragnar Olaffson, representing 4.30 per cent. of the current
issued share capital, with institutional investors at a price of 60p. Following
this, Mr Olaffson holds 1,298,000 ordinary shares, representing 3.72 per cent.
of the current issued share capital and 3.00 per cent. of the issued share
capital as enlarged by the Placing.
1 November 2006
The Directors of Byotrol plc (the 'Company') are pleased to announce that the
Company has entered into two separate distribution agreements with SunChoice
Europe Limited ('SunChoice') and DBM Holdings Ltd ('DBM') to supply Byotrol's
assure product range into the UK care homes market.
SunChoice distributes an extensive range of over 5000 products to more than
1,000 nursing and residential care homes in the UK. The product range includes
cleaning and janitorial products, medical consumables, uniforms and patient
handling equipment.
SunChoice is wholly owned by Southern Cross Healthcare Group
plc, the largest provider of care homes and long term care beds in the UK, which
operates over 570 care homes, providing more than 28,000 beds and employing
around 33,000 staff.
Based in Edinburgh, DBM supplies products to healthcare and retail markets, with
a particular focus on independent care home operators throughout the UK.
Byotrol's assure range has been specifically developed for the care homes sector
and comprises disinfectant sprays for use in living areas, kitchens and
bathrooms, cleaning and sanitising wipes, and a hand sanitising mousse. The
Company's patented technology has been proven, through extensive testing, to be
effective in eradicating and controlling a wide range of organisms such as MRSA,
c.difficile and e-coli. Byotrol remains active after it has dried, providing
anti-microbial protection for extended periods after application and is able
therefore to tackle the practical problems of odours and spoilage caused by
microbe activity.
Byotrol is not toxic to humans and does not require any specialist equipment or
alteration to existing cleaning regimens to be effective. A further advantage of
Byotrol is also its ultra low alcohol content, compared to competing products,
which means it does not dry or irritate the skin when used as a hand sanitiser
as part of infection control procedures.
The Directors anticipate that the agreements with SunChoice and DBM will make a
significant contribution to the Company's future revenues.
Stephen Falder, Byotrol's Deputy Chairman commented:
'We are delighted to be working with SunChoice and DBM, who will be marketing
our assure product range to a significant number of nursing and residential care
homes in the UK. Byotrol has undergone extensive testing and has been shown to
deliver substantial benefits to both residents and healthcare professionals .'
Barbara Hornby, Managing Director for SunChoice Europe commented:
'Working with Byotrol is a significant move for SunChoice Europe to provide a
leading edge, yet proven solution for infection control. We now have the
opportunity to distribute this innovative technology to care homes across the
UK, helping to combat the risk and spread of MRSA and other harmful
micro-organisms.'
Gary Walsh, Marketing Director for DBM stated:
'The partnership with Byotrol enables DBM to provide truly innovative control
methods which are safe to use, compatible with the material they protect and
also comply with increasingly strict regulatory controls. This ground breaking
anti microbial technology will provide care and nursing homes with a truly
unique method of combating the risk and spread of MRSA and other harmful
micro-organisms in higher risk environments. We also believe that the results of
the recent study at Glasgow Royal Infirmary will have a positive impact on
potential customers.'
26 October 2006
The Board of Byotrol plc (the 'Company') is pleased to announce the appointment
of Charles Stanley Securities as the Nominated Adviser and Broker and to the
Company with immediate effect.
